Jandus Camilla

Prof. Camilla Jandus

Tenure-track Assistant Professor



 My main scientific interest is in the study of T cell- and Innate Lymphoid Cell (ILC)- mediated immune responses to human tumors. I have adopted and developed cutting-edge technologies for high-throughput analyses of T cells, at the single cell level, allowing to focus on the quantitative and qualitative evaluation of natural and therapy-induced tumor-specific CD4 T cell responses. I aim to identify the most potent T cells and best-of-class T cell receptors (TCRs), enabling their rapid and cost-effective isolation and validation in clinical trials. In parallel, I am investigating the role of Innate lymphoid cell (ILC) subsets, a recently described family of innate immune effector cells, in the context of anti-tumor immunity. I have been pioneering in reporting the pro-tumoral role of the ILC2 subset in human tumors and I am currently developing strategies to target these cells therapeutically in patients.

Selected publications

  • Ercolano G., Gomez-Cadena A., Dumauthioz N., Vanoni G., Kreutzfeldt M., Wyss T., Michalik L., Loyon R., Ianaro A., Ho P-C., Borg C., Kopf M., Merkler D., Krebs P., Romero P., Trabanelli S. and Jandus C. PPAR drives IL-33 dependent ILC2 pro-tumoral functions. Nat Communications, 2021 May; 12(1):2538
  • CachotA., BilousM., Liu Y-C., LiX., SaillardM., CenerentiM., RockingerGA., WyssT., GuillaumeP., SchmidtJ., GenoletR., ErcolanoG., ProttiMP., ReithW., IoannidouK., de LevalL., TrapaniJA., CoukosG., HarariA., SpeiserDE.,  MathisA., GfellerD., AltugH., RomeroP. and JandusC. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer.Science Adv, 2021 Feb, 7(9):eabe3348
    Salomé B., Gomez-Cadena A., Loyon R., Suffiotti M., Salvestrini V., Wyss T., Vanoni G., Ruan D.F., Rossi M., Tozzo A., Tentorio P., Bruni E., Riether C., Jacobsen E-V., Jandus P., Conrad C., Hoenig M., Schulz A., Michaud K., Della Porta M.G., Salvatore S., Ho P-C., Gfeller D., Ochsenbein A., Mavilio D., Curti A., Marcenaro E., Steinle A., Horowitz A., Romero P., Trabanelli S. and Jandus C. CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML. Blood Advances, 2019 Nov, 3(22):3674-3687
  • Trabanelli S., Chevalier MF., Martinez-Usatorre A., Gomez-Cadena A., Salomé B.,Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C., Morita H., Pizzitola I., Grandclément C., Bohner P., Bruni E., Girorta M., Pallavi R., Falvo P., Leibundgut EO., Baerlocher GM., Carlo-Stella C., Taurino D., Santoro A., Spinelli O., Rambaldi A., Giarin E., Basso G., Tresoldi C., Ciceri F., Gfeller D., Akdis CA., Mazzarella L., Minucci S., Pelicci PG., Marcenaro E., McKenzie ANJ., Vanhecke D., Coukos G., Mavilio D., Curti A., Derré L. and Jandus C. Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.Nat Commun, 2017Sep, 8(1):593
  • Chevalier MF., Trabanelli S., Racle J., CessonV., Gharbi D., Bohner P., Domingos-PereiraS., Dartiguenave F., FritschiA-S., SpeiserDE., RentschCA., Gfeller D., JichlinskiP., Nardelli-HaefligerD., Jandus C.* and Derré L.*, ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. *: equal contribution. J Clin Invest, 2017 Aug, 127 (8):2916-2929